4.35
price down icon1.81%   -0.08
after-market Handel nachbörslich: 4.35
loading
Schlusskurs vom Vortag:
$4.43
Offen:
$4.42
24-Stunden-Volumen:
48,391
Relative Volume:
0.42
Marktkapitalisierung:
$37.58M
Einnahmen:
$140.46M
Nettoeinkommen (Verlust:
$-146.34M
KGV:
-3.4252
EPS:
-1.27
Netto-Cashflow:
$-117.73M
1W Leistung:
+12.99%
1M Leistung:
-3.12%
6M Leistung:
-58.57%
1J Leistung:
-69.80%
1-Tages-Spanne:
Value
$4.35
$4.60
1-Wochen-Bereich:
Value
$3.85
$4.91
52-Wochen-Spanne:
Value
$3.51
$16.95

Karyopharm Therapeutics Inc Stock (KPTI) Company Profile

Name
Firmenname
Karyopharm Therapeutics Inc
Name
Telefon
617-658-0600
Name
Adresse
85 WELLS AVENUE, NEWTON, MA
Name
Mitarbeiter
279
Name
Twitter
@Karyopharm
Name
Nächster Verdiensttermin
2024-11-05
Name
Neueste SEC-Einreichungen
Name
KPTI's Discussions on Twitter

Vergleichen Sie KPTI mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
KPTI
Karyopharm Therapeutics Inc
4.35 38.27M 140.46M -146.34M -117.73M -1.27
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 122.48B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 31.91B 3.81B -644.79M -669.77M -6.24

Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-16 Herabstufung H.C. Wainwright Buy → Neutral
2025-07-11 Fortgesetzt H.C. Wainwright Buy
2023-01-19 Eingeleitet Piper Sandler Overweight
2022-11-04 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2022-02-09 Hochstufung JP Morgan Underweight → Neutral
2021-11-19 Fortgesetzt Morgan Stanley Equal-Weight
2021-08-06 Herabstufung JP Morgan Overweight → Neutral
2021-08-06 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2021-08-06 Herabstufung SVB Leerink Outperform → Mkt Perform
2020-07-02 Eingeleitet Morgan Stanley Overweight
2020-03-04 Eingeleitet Barclays Overweight
2020-01-17 Herabstufung Wedbush Outperform → Neutral
2019-07-23 Hochstufung JP Morgan Neutral → Overweight
2019-07-05 Bestätigt H.C. Wainwright Buy
2019-07-05 Bestätigt Robert W. Baird Outperform
2019-03-01 Herabstufung JP Morgan Overweight → Neutral
2019-02-28 Bestätigt BofA/Merrill Underperform
2019-02-27 Herabstufung BofA/Merrill Neutral → Underperform
2019-01-03 Hochstufung BofA/Merrill Underperform → Neutral
2018-12-03 Eingeleitet B. Riley FBR Buy
2018-11-09 Hochstufung Wedbush Neutral → Outperform
2018-05-24 Herabstufung Wedbush Outperform → Neutral
2018-04-02 Fortgesetzt Leerink Partners Outperform
2017-11-15 Fortgesetzt H.C. Wainwright Buy
2017-09-15 Eingeleitet RBC Capital Mkts Outperform
2016-09-08 Bestätigt H.C. Wainwright Buy
2016-08-30 Hochstufung Jefferies Hold → Buy
2016-08-18 Eingeleitet H.C. Wainwright Buy
2016-06-28 Eingeleitet Robert W. Baird Outperform
Alle ansehen

Karyopharm Therapeutics Inc Aktie (KPTI) Neueste Nachrichten

pulisher
02:33 AM

What drives Karyopharm Therapeutics Inc. stock priceConsistently high returns - PrintWeekIndia

02:33 AM
pulisher
06:23 AM

Karyopharm Therapeutics Inc. Stock Analysis and ForecastFast-track wealth growth - PrintWeekIndia

06:23 AM
pulisher
04:35 AM

What analysts say about Karyopharm Therapeutics Inc. stockUnprecedented market success - Autocar Professional

04:35 AM
pulisher
Jul 24, 2025

How high can Karyopharm Therapeutics Inc. stock price go in 2025High-yield market plays - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 23, 2025

Triple Refractory Multiple Myeloma Market Forecast 2032: - openPR.com

Jul 23, 2025
pulisher
Jul 23, 2025

Is Karyopharm Therapeutics Inc. a good long term investmentRapid wealth multiplication - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Layoff Tracker: GSK, Sail, BioNTech Cut Staff for Second Time This Year - BioSpace

Jul 22, 2025
pulisher
Jul 22, 2025

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Eastern Progress

Jul 22, 2025
pulisher
Jul 18, 2025

Will Karyopharm Therapeutics Inc. stock split in the near futureHigh Return Intraday Picks - Newser

Jul 18, 2025
pulisher
Jul 17, 2025

HC Wainwright & Co. Downgrades Karyopharm Therapeutics (KPTI) - MSN

Jul 17, 2025
pulisher
Jul 16, 2025

H.C. Wainwright downgrades Karyopharm stock to Neutral amid financial concerns - Investing.com Canada

Jul 16, 2025
pulisher
Jul 15, 2025

Finance Watch: Karyopharm Cuts Jobs In Cash Crunch; Pacira’s Layoffs Attributed To Efficiency - insights.citeline.com

Jul 15, 2025
pulisher
Jul 15, 2025

How Karyopharm Therapeutics Inc. stock performs during market volatilityTop Performing Low Risk Stocks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Karyopharm Therapeutics Inc. stock price move sharplyROI Driven Alerts - beatles.ru

Jul 15, 2025
pulisher
Jul 15, 2025

Why Karyopharm Therapeutics Inc. stock attracts strong analyst attentionFree Stock Market Expert Consultation - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Newton biotech cuts over 50 jobs, and other biotech news - The Business Journals

Jul 15, 2025
pulisher
Jul 13, 2025

HC Wainwright Initiates Coverage on Karyopharm Therapeutics (NASDAQ:KPTI) - Defense World

Jul 13, 2025
pulisher
Jul 12, 2025

Karyopharm Therapeutics: A Liquidity Crossroads with Little Room to Pivot - AInvest

Jul 12, 2025
pulisher
Jul 11, 2025

Karyopharm stock tumbles after disclosing failed financing talks By Investing.com - Investing.com South Africa

Jul 11, 2025
pulisher
Jul 11, 2025

Karyopharm Shares Slide After Financing Efforts Stall, Strategic Review Underway - MSN

Jul 11, 2025
pulisher
Jul 11, 2025

Karyopharm's Freefall: What's Driving the Collapse? - AInvest

Jul 11, 2025

Finanzdaten der Karyopharm Therapeutics Inc-Aktie (KPTI)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Karyopharm Therapeutics Inc-Aktie (KPTI) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Paulson Richard A.
President and CEO
May 06 '25
Sale
7.12
236
1,680
82,503
Rangwala Reshma
EVP & Chief Medical Officer
Apr 23 '25
Sale
6.17
419
2,585
28,853
Paulson Richard A.
President and CEO
Apr 04 '25
Sale
3.74
245
916
82,739
Cheng Sohanya Roshan
EVP & Chief Commercial Officer
Mar 04 '25
Sale
6.29
3,445
21,669
34,314
Paulson Richard A.
President and CEO
Mar 04 '25
Sale
6.29
11,694
73,555
82,984
Rangwala Reshma
EVP & Chief Medical Officer
Mar 04 '25
Sale
6.29
3,587
22,562
29,272
Poulton Stuart
EVP, Chief Development Officer
Mar 04 '25
Sale
6.29
3,548
22,317
27,414
Mano Michael
SVP, General Counsel&Secretary
Mar 04 '25
Sale
6.29
2,793
17,568
21,047
Poulton Stuart
EVP, Chief Development Officer
Feb 18 '25
Sale
0.63
5,914
3,726
320,714
Paulson Richard A.
President and CEO
Feb 04 '25
Sale
0.65
4,099
2,664
1,120,158
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Kapitalisierung:     |  Volumen (24h):